Comparison between Sasken Communication Technologies IPO and Vivimed Labs IPO.
Sasken Communication Technologies IPO is a Mainboard Fixed Price IPO proposed to list at BSE, NSE while Vivimed Labs IPO is a Mainboard Fixed Price proposed to list at BSE, NSE.
The total issue size of Sasken Communication Technologies IPO is up to ₹130.00 Cr whereas the issue size of the Vivimed Labs IPO is up to ₹17.51 Cr. The final issue price of Sasken Communication Technologies IPO is ₹260.00 per share and of Vivimed Labs IPO is ₹70.00 per share.
| Sasken Communication Technologies IPO | Vivimed Labs IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹230.00 per share | |
| Issue Price (Upper) | ₹260.00 per share | |
| Issue Price (Final) | ₹260.00 per share | ₹70.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 50,00,000 shares | 25,01,429 shares |
| Fresh Issue Size (Amount) | up to ₹130.00 Cr | up to ₹17.51 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 50,00,000 shares | 25,01,429 shares |
| Issue Size Total (Amount) | up to ₹130.00 Cr | up to ₹17.51 Cr |
Sasken Communication Technologies IPO opens on Aug 11, 2005, while Vivimed Labs IPO opens on Jul 09, 2005. The closing date of Sasken Communication Technologies IPO and Vivimed Labs IPO is Aug 17, 2005, and Jul 13, 2005, respectively.
Sasken Communication Technologies IPO P/E ratio is 25.69, as compared to Vivimed Labs IPO P/E ratio of .
| Sasken Communication Technologies IPO | Vivimed Labs IPO | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated)
| |||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 30.98 | 55.13 | |||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 25.35 | 36.14 | |||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 25.69 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹715.30 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | |||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | |||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹10.12 | ||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 12.74 | 23.14 | |||||||||||||||||||||||||||||||||||||||||||||||
In the Sasken Communication Technologies IPO Retail Individual Investors (RII) are offered 13,50,000 shares while in Vivimed Labs IPO retail investors are offered 13,50,000 shares. Qualified Institutional Buyers (QIB) are offered 27,00,000 shares in Sasken Communication Technologies IPO and 0 shares in Vivimed Labs IPO.
| Sasken Communication Technologies IPO | Vivimed Labs IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 27,00,000 shares | 0 shares |
| NII | 4,50,000 shares | 9,25,000 shares |
| RII | 13,50,000 shares | 9,25,000 shares |
| Employee | 5,00,000 shares | 50,000 shares |
| Others | ||
| Total | 50,00,000 shares | 25,00,000 shares |
Sasken Communication Technologies IPO subscribed in total, whereas Vivimed Labs IPO subscribed .
